Authors

Tao Huang*,#, Qian Li*, Wei Huang*, Huihui Li*, Tong Sun*, Zhirong Wang**

Departments

*Department of Cardiology, Suzhou City Hospital, Suzhou, PR China - **Department of Cardiology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, PR China

Abstract

Objective: To investigate the effects of atorvastatin combined with trimetazidine on coagulation index, hemorheology, blood lipid, cytokine level and oxidative stress markers in patients with coronary heart disease.

Methods: 90 patients with coronary heart disease admitted to our hospital from January 2017 to December 2017 were selected. According to different treatment methods, the patients were divided into control group (n=45) and observation group (n=45). All patients were treated with conventional therapy (vasodilator substance, oxygen inhalation, diuretics) after admission. The patients in the control group were given atorvastatin orally, 20 mg each time, once a day. On the basis of treatment in the control group, the observation group was given trimetazidine tablets orally, 20 mg each time, 3 times a day. Both groups were treated continuously for 3 months. The clinical efficacy and adverse reactions of the two groups were observed, and the coagulation indexes of the two groups: plasma plasminogen activating inhibitor 1 (PAI-1), tissue plasminogen activator (t-PA), von Willebrand factor (vWF), erythrocyte sedimentation rate, whole blood viscosity, plasma viscosity, low density lipoprotein cholesterol (LDL-C), glycerin trilaurate (TG), total cholesterol (TC), malondialdehyde (MDA), superoxide dismutase (SOD), N-terminal pro-B-type natriuretic peptide (NT-proBNP), high sensitive C-reactive protein (hs-CRP) and tumor necrosis factor α (TNF-α) were compared.

Results: The effective rate of the observation group was 93.33%, which was significantly higher than that of the control group (P<0.05). After treatment, the levels PAI-1 and vWF of the two groups was remarkably lower than that before treatment, and t-PA level of the two groups was significantly higher than that before treatment (P<0.05). Moreover, PAI-1 and vWF levels of the patients in the observation group was markedly lower than that in the control group, and t-PA level in the observation group was obviously higher than that in the control group (P<0.05). After treatment, the whole blood viscosity, plasma viscosity and hematocrit of the two groups were significantly lower than those before treatment (P<0.05). Furthermore, the whole blood viscosity, plasma viscosity and hematocrit in the observation group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of LDL-L, TG and TC in the two groups was remarkably lower than that before treatment (P<0.05) and LDL-L, TG and TC levels in the observation group was significantly lower than that in the control group (P<0.05). After treatment, the levels of NT-proBNP, hs-CRP and TNF-α in the two groups was markedly lower than that before treatment (P<0.05), and NT-proBNP, hs-CRP and TNF-α levels in the observation group was significantly lower than that in the control group (P<0.05). In addition, there were no serious adverse reactions in both groups.

Conclusion: Atorvastatin combined with trimetazidine is effective in the treatment of coronary heart disease with few adverse reactions. It can effectively improve the coagulation index, hemorheology, blood lipid level, decrease the level of NT-proBNP, hs-CRP, TNF-α, and play an anti-inflammatory role.

Keywords

Atorvastatin, trimetazidine, coronary heart disease, coagulation index, hemorheology, blood lipid, cytokines, oxidative stress.

DOI:

10.19193/0393-6384_2019_6_486